Potential treatment with Chinese and Western medicine targeting NSP14 of SARS-CoV-2

Chao Liu; Xiaoxiao Zhu; Yiyao Lu; Xianqin Zhang; Xu Jia; Tai Yang

doi:10.1016/j.jpha.2020.08.002

Volume 11 Issue 3

Jun. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2021 > 11(3): 272-277

Chao Liu, Xiaoxiao Zhu, Yiyao Lu, Xianqin Zhang, Xu Jia, Tai Yang. Potential treatment with Chinese and Western medicine targeting NSP14 of SARS-CoV-2[J]. Journal of Pharmaceutical Analysis, 2021, 11(3): 272-277. doi: 10.1016/j.jpha.2020.08.002

Citation:

Chao Liu, Xiaoxiao Zhu, Yiyao Lu, Xianqin Zhang, Xu Jia, Tai Yang. Potential treatment with Chinese and Western medicine targeting NSP14 of SARS-CoV-2[J]. Journal of Pharmaceutical Analysis, 2021, 11(3): 272-277. doi: 10.1016/j.jpha.2020.08.002

Citation:

PDF( 1412 KB)

Potential treatment with Chinese and Western medicine targeting NSP14 of SARS-CoV-2

doi: 10.1016/j.jpha.2020.08.002

Chao Liu^a,
Xiaoxiao Zhu^a,
Yiyao Lu^a,
Xianqin Zhang^a,b,
Xu Jia^{a
,
,},
Tai Yang^{c
,
,}

a. Non-coding RNA and Drug Discovery Key Laboratory of Sichuan Province, Chengdu Medical College, Chengdu, Sichuan, 610500, China;
b. Basic Medical School, Chengdu Medical College, Chengdu, Sichuan, 610500, China;
c. School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan, 610500, China

Funds:

This work was supported by grants from the National Natural Science Foundation of China (Grant Nos. 31870135, 31600116) and the “1000 Talent Plan” of Sichuan Province (No. 980).

Received Date: Mar. 24, 2020
Accepted Date: Aug. 06, 2020
Rev Recd Date: Jul. 02, 2020
Available Online: Jan. 24, 2022
Publish Date: Jun. 15, 2021

Abstract

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a serious global health threat. This raises an urgent need for the development of effective drugs against the deadly disease. SARS-CoV-2 non-structural protein 14 (NSP14) carrying RNA cap guanine N7-methyltransferase and 3′-5′ exoribonuclease activities could be a potential drug target for intervention. NSP14 of SARS-CoV-2 shares 98.7% of similarity with the one (PDB 5NFY) of acute respiratory syndrome (SARS) by ClustalW. Then, the SARS-CoV-2 NSP14 structures were modelled by Modeller 9.18 using SARS NSP14 (PDB 5NFY) as template for virtual screening. Based on the docking score from AutoDock Vina1.1.2, 18 small molecule drugs were selected for further evaluation. Based on the 5 ns MD simulation trajectory, binding free energy (ΔG) was calculated by MM/GBSA method. The calculated binding free energies of Saquinavir, Hypericin, Baicalein and Bromocriptine for the N-terminus of the homology model were −37.2711 ± 3.2160, −30.1746 ± 3.1914, −23.8953 ± 4.4800, and −34.1350 ± 4.3683 kcal/mol, respectively, while the calculated binding free energies were −60.2757 ± 4.7708, −30.9955 ± 2.9975, −46.3099 ± 3.5689, and −59.8104 ± 3.5389 kcal/mol, respectively, when binding to the C-terminus. Thus, the compounds including Saquinavir, Hypericin, Baicalein and Bromocriptine could bind to the N-terminus and C-terminus of the homology model of the SARS-CoV-2 NSP14, providing a candidate drug against SARS-CoV-2 for further study.
- SARS-CoV-2,
- Nonstructural protein 14 (NSP14),
- ZINC database,
- Drug docking

FullText(HTML)

References(26)

References

Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 367(6483) (2020) 1260-1263. https://doi: 10.1126/science.abb2507

Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 30(4) (2020) 343-355. https://doi: 10.1038/s41422-020-0305-x

Rabaan AA, Al-Ahmed SH, Haque S, et al. SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Infez Med. 28 (2020) 174-184

Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382 (2020) 727-733. https://doi: 10.1056/NEJMoa2001017

Ferron F, Subissi L, Silveira De Morais AT, et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc Natl Acad Sci U S A. 115 (2018) E162-E171. https://doi: 10.1073/pnas.1718806115

Snijder EJ, Decroly E, Ziebuhr J. The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing. Adv Virus Res. 96 (2016) 59-126. https://doi: 10.1016/bs.aivir.2016.08.008

I. Sola, F. Almazán, S. Zúñiga, et al., Continuous and discontinuous RNA synthesis in coronaviruses, Annu. Rev. Virol. 2 (2015) 265-288

Ma Y, Wu L, Shaw N, et al. Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex. Proc Natl Acad Sci U S A. 112 (2015) 9436-9441. https://doi: 10.1073/pnas.1508686112

Decroly E, Ferron F, Lescar J, Canard B. Conventional and unconventional mechanisms for capping viral mRNA. Nat Rev Microbiol. 10 (2011) 51-65. Published 2011 Dec 5. https://doi: 10.1038/nrmicro2675

Hage-Melim LIDS, Federico LB, de Oliveira NKS, et al. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19 [published online ahead of print, 2020 Jun 11]. Life Sci. 256 (2020) 117963. https://doi: 10.1016/j.lfs.2020.117963

Pant S, Singh M, Ravichandiran V, Murty USN, Srivastava HK. Peptide-like and small-molecule inhibitors against Covid-19 [published online ahead of print, 2020 May]. J. Biomol. Struct. Dyn. (2020) 1-10. https://doi: 10.1080/07391102.2020.1757510

Choy KT, Wong AY, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 178 (2020) 104786. https://doi: 10.1016/j.antiviral.2020.104786

Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: the reality and challenges. J. Microbiol. Immunol. Infect. 53 (2020) 436-443. https://doi: 10.1016/j.jmii.2020.03.034

Chen P, Jiang M, Hu T, Liu Q, Chen XS, Guo D. Biochemical characterization of exoribonuclease encoded by SARS coronavirus. J. Biochem. Mol. Biol. 40 (2007) 649-655. https://doi: 10.5483/bmbrep.2007.40.5.649

Hamdan S, Carr PD, Brown SE, Ollis DL, Dixon NE. Structural basis for proofreading during replication of the Escherichia coli chromosome. Structure. 10 (2002) 535-546. https://doi: 10.1016/s0969-2126(02)00738-4

Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet. 345(1995) 952-955. https://doi: 10.1016/s0140-6736(95)90699-1

la Porte CJ. Saquinavir, the pioneer antiretroviral protease inhibitor. Expert Opin Drug Metab Toxicol. 5(2009) 1313-1322. https://doi: 10.1517/17425250903273160

Beck BR, Shin B, Choi Y, Park S, Kang K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 18(2020) 784-790. https://doi: 10.1016/j.csbj.2020.03.025

Karioti A, Bilia AR. Hypericins as potential leads for new therapeutics. Int J Mol Sci. 11(2010) 562-594. https://doi: 10.3390/ijms11020562

Lenard J, Rabson A, Vanderoef R. Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: inhibition of fusion and syncytia formation. Proc Natl Acad Sci U S A. 90(1993) 158-162. https://doi: 10.1073/pnas.90.1.158

Zhang GH, Wang Q, Chen JJ, Zhang XM, Tam SC, Zheng YT. The anti-HIV-1 effect of scutellarin. Biochem Biophys Res Commun. 334(2005) 812-816. https://doi: 10.1016/j.bbrc.2005.06.166

Sithisarn P, Michaelis M, Schubert-Zsilavecz M, Cinatl J Jr. Differential antiviral and anti-inflammatory mechanisms of the flavonoids biochanin A and baicalein in H5N1 influenza A virus-infected cells. Antiviral Res. 97(2013) 41-48. https://doi: 10.1016/j.antiviral.2012.10.004

Hour MJ, Huang SH, Chang CY, et al. Baicalein, Ethyl Acetate, and Chloroform Extracts of Scutellaria baicalensis Inhibit the Neuraminidase Activity of Pandemic 2009 H1N1 and Seasonal Influenza A Viruses. Evid Based Complement Alternat Med. 2013 (2013) 750803. https://doi: 10.1155/2013/750803

Keum Y S, L.J.M., Yu M S, et al., Inhibition of SARS Coronavirus Helicase by Baicalein. Bulletin of the Korean Chemical Society, 34(2013) 3187-3188. https://DOI: dx.doi.org/10.5012/bkcs.2013.34.11.3187

Kato F, Ishida Y, Oishi S, et al. Novel antiviral activity of bromocriptine against dengue virus replication. Antiviral Res. 131(2016) 141-147. https://doi: 10.1016/j.antiviral.2016.04.014

Chan JF, Chik KK, Yuan S, et al. Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B-NS3 protease inhibitor. Antiviral Res. 141(2017) 29-37. https://doi: 10.1016/j.antiviral.2017.02.002

Relative Articles

Supplements(0)

Cited By

Proportional views